Search Results
123 items found for "cancer immunotherapy"
- Ep 75 with Vaithish Velazhahan
His undergraduate thesis work on studying the biochemical mechanisms of flavonoids in cancer using nuclear
- Ep 157 with Dr. Nagarajan Vaidehi
She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr.
- GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment
Lorazepam, which has off target agonism of GPR68, is linked to worse clinical outcomes for a variety of cancers However, the role of tumor microenvironment acidification in GPR68 activation has not been assessed in cancer
- Ep 136 with Murat Tunaboylu & Ben Holland
After switching to biotech, Murat has built cell imaging software and lab robots to accelerate cancer
- Ep 92 with Dr. Stephane Angers
development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers
- Student Flash Presentations | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Role Of GPR97/ADGRG3 In Neutrophil Biology Tyler Bernadyn Next Generation MBD2 inhibitors for Brain Cancer Formation in Li-Fraumeni Syndrome Alex Torrelli-Diljohn Abstract "Li-Fraumeni syndrome (LFS) is a rare cancer El Merahbi Rabih, Herzig Stephan , Georgiadi A , Helmholtz Center Munich, Institute of Diabetes and Cancer Research Group to identify novel prognostic biomarkers and therapeutic options for Metastatic Breast Cancer Tyler Bernadyn on the web LinkedIn Next Generation MBD2 inhibitors for Brain Cancer Therapy Jesse Stillwell
- CB2 stimulation of adipose resident ILC2s orchestrates immune balance and ameliorates type 2 diabetes mellitus
Tags CB2 , CP: Immunology , CP: Metabolism , ILC2 , T2DM , adipose inflammation , glucose tolerance , immunotherapy
- CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases
This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple
- Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
GPRC5D), an orphan GPCR predominantly expressed in MM cells, is emerging as a promising target for MM immunotherapy
- High expression of GPR50 promotes the proliferation, migration and autophagy of hepatocellular carcinoma cells in vitro
Previous studies have indicated that GPR50 could protect against breast cancer development and decrease
- GPCRs and fibroblast heterogeneity in fibroblast-associated diseases
such as idiopathic pulmonary fibrosis, cardiac fibrosis, pancreatic fibrosis, hepatic fibrosis, and cancer
- Distinct sub-cellular signal propagation as a component of functional selectivity
of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer
- Dynamic Phosphoproteomics of BRS3 Activation Reveals the Hippo Signaling Pathway for Cell Migration
The lung cancer cell line H1299-BRS3 was treated with MK-5046, an agonist of BRS3, for different durations
- A virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P1 signaling axis
kinases AKT and CHK1 and the transcriptional regulators cMYC and STAT3 and by increasing the abundance of cancerous
- Unveiling Non-Canonical Functions for Gαq Signaling Pathways
(GRK2), a known regulator of Gq-GPCR signaling in HNSCC tumor progression (International Journal of Cancer
- "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways
Caron on the web UNC-Chapel Hill Department of Cell Biology and Physiology UNC Lineberger Comprehensive Cancer
- Ep 43 with Dr. Stuart Maudsley
At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional
- S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
genes are promising therapeutic targets and plausible new innovation avenues to combat IM resistance in cancer
- Ep 72 with Dr. Stuart Maudsley
At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional
- Ep 78 with Dr. Stuart Maudsley
At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional
- Ep 151 with Dr GPCR Board
control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation, and cancer
- Evolutionary diversity of CXCL16-CXCR6: Convergent substitutions and recurrent gene loss in sauropsids
This axis is linked to diseases like HIV/SIV, cancer, and COVID-19.
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
of regenerating liver 3 (PRL3) is a specific tumor antigen overexpressed in a broad range of adult cancer
- Ep 60 with Dr. Josephine (Pina) Cardarelli
The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers
- Identification of S1PR4 as an immune modulator for favorable prognosis in HNSCC through machine learning
Authors Chenshen Huang , Fengshuo Zhu , Hao Zhang , Ning Wang , Qi Huang Tags Cancer , Machine learning
- Ep 36 with Dr. Michel Bouvier
of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer
- GPCR Retreat 2023 | Dr. GPCR Ecosystem
world-class and diverse GPCR scientists working in the arenas of structure and signaling, neuroscience, cancer
- Ep 50 with Dr. Thomas P. Sakmar
and Ping Chi , that a mutant of CYSLTR2 is a driver oncogene in uveal melanoma, the most common eye cancer